When you and your doctor discuss CAR T-cell therapy as a potential treatment option for you, it may be helpful to have In addition to speaking with your doctor, LLS Information Specialists, available at (800) 955-4572, offer guidance on how patients can work with their doctors to determine if a specific clinical trial is an appropriate treatment option.
LLS offers highly personalized clinical-trial search services, which can be accessed through our Information Specialists.
It is a CD19-directed genetically modified autologous T cell immunotherapy. Axicabtagene ciloleucel (Yescarta) is FDA approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
The therapy has resulted in long-term remissions for some types of blood cancer.
There are three types of lymphocytes Immune cells or antibodies can be produced in the laboratory under tightly controlled conditions and then given to patients to treat cancer.AIU is doing its part by making learning materials, college courses, and academic research Publicly Accessible.To view all of AIU's open / free courses click here.After this reengineering, the T cells are known as “chimeric antigen receptor (CAR) T cells.” CARs are proteins that allow the T cells to recognize an antigen on targeted tumor cells. The number of the patient’s genetically modified T cells is “expanded” by growing cells in the laboratory.When there are enough of them, these CAR T cells are frozen and sent to the hospital or center where the patient is being treated.